27421-65-4

Upstream product

• 6610-29-3 4-methylthiosemicarbazide 
• 98-86-2 acetophenone 
• 52756-49-7 C₉H₈N₂S 
• 74-89-5 methylamine 
• 13466-30-3 (1-phenylethylidene)hydrazine 

Downstream Products

• 26365-36-6 1,3-dimethyl-1-[5-oxo-4-(1-phenyl-ethyl)-4,5-dihydro-[1,3,4]thiadiazol-2-yl]-urea 
• 26365-37-7 trimethyl-[5-oxo-4-(1-phenyl-ethyl)-4,5-dihydro-[1,3,4]thiadiazol-2-yl]-urea 
• 27422-17-9 methyl-[5-oxo-4-(1-phenyl-ethyl)-4,5-dihydro-[1,3,4]thiadiazol-2-yl]-carbamoyl chloride 
• 1357348-61-8 Pd(κ3-C4,N3,S-acetophenone-N-methylthiosemicarbazonato) 
• 27434-48-6 4-methyl-1-(1-phenyl-ethyl)-thiosemicarbazide 

Relevant academic research and scientific papers

Organometallic ruthenium(II) complexes containing NS donor Schiff bases: Synthesis, structure, electrochemistry, DNA/BSA binding, DNA cleavage, radical scavenging and antibacterial activities

Four new cyclopentadienylruthenium(II)-acetophenone-4(N)-substituted thiosemi-carbazone complexes, with the general formula [Ru(?5-C5H5)(H-Aptsc)PPh3].Cl (1), [Ru(?5-C5H5)(H-Apmt

Synthesis, characterization, and anticancer activity of a series of ketone-N4-substituted thiosemicarbazones and their ruthenium(II) arene complexes

A series of ketone-N4-substituted thiosemicarbazone (TSC) compounds (L1-L9) and their corresponding [(η6-p-cymene)Ru II(TSC)Cl]+/0 complexes (1-9) were synthesized and characterized by NMR, IR, elemental analysis, and HR-ESI-mass spectrometry. The molecular structures of L4, L9, 1-6, and 9 were determined by single-crystal X-ray diffraction analysis. The compounds were further evaluated for their in vitro antiproliferative activities against the SGC-7901 human gastric cancer, BEL-7404 human liver cancer, and HEK-293T noncancerous cell lines. Furthermore, the interactions of the compounds with DNA were followed by electrophoretic mobility spectrometry studies.

M-STAGE KINESIN INHIBITOR

A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, -C(=W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents -C(=Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.

THIADIAZOLINE DERIVATIVE

(wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents -C(-W)R6 or the like; R3 represents a hydrogen atom, -C(=WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.